Valley National Advisers Inc buys $795,419 stake in Pfizer (PFE)

Pfizer (PFE) : Valley National Advisers Inc scooped up 2,615 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 23,908 shares of Pfizer which is valued at $795,419.Pfizer makes up approximately 0.42% of Valley National Advisers Inc’s portfolio.

Pfizer closed down -0.05 points or -0.15% at $33 with 2,60,94,478 shares getting traded on Wednesday. Post opening the session at $32.98, the shares hit an intraday low of $32.9 and an intraday high of $33.21 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Strs Ohio sold out all of its stake in PFE during the most recent quarter. The investment firm sold 4,315,678 shares of PFE which is valued $143,582,607.Community Bank N.a. reduced its stake in PFE by selling 152 shares or 0.14% in the most recent quarter. The Hedge Fund company now holds 105,226 shares of PFE which is valued at $3,500,869. Pfizer makes up approx 0.83% of Community Bank N.a.’s portfolio.Beech Hill Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 2,594 additional shares and now holds a total of 165,719 shares of Pfizer which is valued at $5,513,471. Pfizer makes up approx 4.27% of Beech Hill Advisors’s portfolio.Simplex Trading reduced its stake in PFE by selling 182,897 shares or 85.51% in the most recent quarter. The Hedge Fund company now holds 30,987 shares of PFE which is valued at $1,007,078. Pfizer makes up approx 0.16% of Simplex Trading’s portfolio.Endurance Wealth Management reduced its stake in PFE by selling 11,493 shares or 5.59% in the most recent quarter. The Hedge Fund company now holds 194,236 shares of PFE which is valued at $6,312,670. Pfizer makes up approx 1.22% of Endurance Wealth Management’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.